A Study of AdCh63 ME-TRAP Alone and With MVA ME-TRAP

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

August 31, 2011

Study Completion Date

September 30, 2011

Conditions
Malaria
Interventions
BIOLOGICAL

AdCh63 ME-TRAP

"1. A:Intradermal injection 1x10\^8 vp at day 0~2. A:Intradermal injection 1x10\^9 vp at day 0~3. A:Intradermal injection 1x10\^10 vp at day 0~4. A:Intradermal injection 5x10\^10 vp at day 0~5:Intramuscular injection 1x10\^10 vp at day 0~6A:Intramuscular injection 5x10\^10 vp at day 0~7A: Intramuscular injection 2x10\^11 vp at day 0"

BIOLOGICAL

AdCh63 ME-TRAP; MVA ME-TRAP

"1. B: AdCh63 ME-TRAP intradermally at dose of 1x10\^8 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)~2. B: AdCh63 ME-TRAP intradermally at dose of 1x10\^9 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)~3. B: AdCh63 ME-TRAP intradermally at dose of 1x10\^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)~4. B: AdCh63 ME-TRAP intradermally at dose of 5x10\^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)~6B: AdCh63 ME-TRAP intramuscularly at dose of 5x10\^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)~7B and 7C: AdCh63 ME-TRAP intramuscularly at dose of 2x10\^11 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)"

Trial Locations (2)

HA1 3UJ

Lister Ward, Department of Infection and Tropical Medicine, Northwick Park Hospital, Harrow

OX3 7LJ

Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Churchill Hospital, Oxford

All Listed Sponsors
lead

University of Oxford

OTHER

NCT00890019 - A Study of AdCh63 ME-TRAP Alone and With MVA ME-TRAP | Biotech Hunter | Biotech Hunter